EUVIMEDEUVIMED entdecken
Leitlinie

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Harold J Burstein iD, Angela DeMichele iD, Mark R Somerfield iD, N Lynn Henry iD, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels

Journal of Clinical Oncology · 20.06.2023 · 41 (18) · 3423-3425

DOI: 10.1200/jco.23.00638 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2023. Verfasst von Harold J Burstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dana Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEstrogen Receptor alphaFemaleHumansErb-b2 Receptor Tyrosine KinasesMutation

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanESR1 protein, humanEstrogen Receptor alpha

Autor:innen und Institutionen

  • Dana Farber Cancer Institute, Boston, MA.
  • University of Pennsylvania, Philadelphia, PA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • University of Michigan, Ann Arbor, MI.

ORCID-Profile: Harold J Burstein, Angela DeMichele, Mark R Somerfield, N Lynn Henry

Zitieren

APA

Burstein, H. J., DeMichele, A., Somerfield, M. R., Henry, N. L., & Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels (2023). Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology, 41(18), 3423-3425. https://doi.org/10.1200/jco.23.00638

Vancouver

Burstein HJ, DeMichele A, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels. Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2023;41(18):3423-3425. doi:10.1200/jco.23.00638

BibTeX
@article{Burstein2023,
  author = {Burstein, Harold J and DeMichele, Angela and Somerfield, Mark R and Henry, N Lynn and Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels},
  title = {Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {18},
  pages = {3423--3425},
  doi = {10.1200/jco.23.00638}
}
Kostenlos starten →